A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1).

Trial Profile

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1).

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Tivozanib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TIVO-1
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 05 Oct 2017 According to an Aveo Oncology media release, the results from TIVO-3 and the TIVO-1 trial will support regulatory approval of tivozanib in the U.S. as a first and third line treatment for RCC
    • 28 Aug 2017 Results published in an AVEO Oncology Media Release.
    • 28 Aug 2017 According to an AVEO Oncology media release, European Commission (EC) has approved FOTIVDA (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top